• Journal of Fisheries and Marine Sciences Education
• /
• v.24 no.2
• /
• pp.203-209
• /
• 2012

We investigated the effect on dietary EPA (eicosapentaenoic acid) source (EP) into formulated diets for growth of brackish flea, Diaphanosoma celebensis. The highest density and specific growth rate (SGR) of brackish fleas were observed on Tetraselmis suecica (TE) trial, but these of trial were not significantly differed with that of Chlorella (CH) + Crypthecodinium sp. (CR) + EP trial, contained EPA oil (P>0.05). Contrastively, CH trial showed the lowest SGR. And in the RNA/DNA ratio, 0.08 of TE trial was the highest ratio out of whole trials, but the trial not significantly differed with that of CH + CR + EP trial (P>0.05). But, the ratio of CH trial was the lowest ratio at 0.05 out of whole trials (P<0.05). Through out results, the EPA source for flea culture was showed a positive effect through their growth and SGR. Therefore, we suggested that a usage of the source with CH could replace T. suecica as good diet for culture of the brackish flea.

• The Korean Society of Law and Medicine
• /
• v.12 no.1
• /
• pp.257-285
• /
• 2011

This thesis has studied about the legal characteristic of injection of the trial drug, the position of the pharmaceutical firm as a contractor of the clinical trial, the possibility of compulsory performance of consistent injection of the trial drug, and the damage claim caused in the process of the clinical trial from the viewpoint of protecting the trial subject in the clinical trial. According to court's judgement in the United States, the lawsuit of the trial subject, although the trial subject had expected consistent injections, was dismissed because there was no direct contract between pharmaceutical and trial subject. However, Helsinki Declaration prescribe the medical research as follows. 'All patients who participated in the research should be able to use the best precaution, diagnosis, and treatment proved by the final outcome of the research'. The trial subject is entitled to demand only the pharmaceutical firm which developed and provided the trial drug, and the pharmaceutical firm has the obligation to supply the trial drug to the trial subject. Therefore, it would be not enough to protect the trial subject if the pharmaceutical firm which makes the trial drug is ruled out. In addition, especially, in case the trial drug has a constant effect with the aim of treatment, if the injection of the trial drug is suddenly stopped, the trial subject would not have the benefit of treatment by the trial drug. In this case, the best remedy against the damage is to urge a constant injection of the trial drug. Thus, in certain case, it is reasonable to consider that the pharmaceutical firm has the obligation to supply the trial drug to the trial subject constantly, and it is also necessary to compel it through effective means in case the pharmaceutical firm do not fulfill its obligation to supply the trial drug. However, as an essential prerequisite for the assertion mentioned above, it should be judged under the principle of good faith considering the concrete situation, that is, what roles the pharmaceutical firm has played.

• Journal of Acupuncture Research
• /
• v.23 no.6
• /
• pp.1-8
• /
• 2006

Introduction : Even though Acupuncture has been know for its effect for a long time, recently it is required to verifiy its effect. To solve this, clinical trial, based on EBM, has been the way to explain acupuncture's treatment effect. Methods: Last year we had a clinical trial based on acupuncture. From this experience we came to a conclusion mentioned below. Results : 1. To find out acupuncture's effect more certainly, it is needed that Korean medical method or treatment should be connected to diagnosis. 2. We had found out that sham and minimal acupuncture are the most appropriate way in single blinding. 3. It is required for the acupuncturist to practice the right real acupuncture point and sham's point in clinical trial. 4. The most important thing to maintain the subjects from dropping out is to always be concerned to the subjects and management them. Conclusion : The best way to advance clinical trial on acupuncture is to use single blinding system with sham acupuncture together in controlled groups and most of all also needs a standardized acupuncture point and depth.

• The Journal of Internal Korean Medicine
• /
• v.16 no.2
• /
• pp.136-145
• /
• 1995

In order to investigate the effect of Dohongsamultang and Dansameum upon restrain of thorombus formation through the experimental study, following conclusion has been obtained; 1. The number of plateletes was increased in the trial group compared with the control group, revealed significance in both of trial groups. 2. Fibrinogen was increased in trial group compared with control group, but the significance was revealed only in Sample I group of Dohongsamultang. 3. Prothrombin time was shortened in both of trial groups, but the significance was revealed in Sample I group of Dohongsa-multang. 4. FDP was decreased in both of trial groups, but the significance was revealed in Sample I group of Dohongsamultang.

• Korean Journal of Applied Biomechanics
• /
• v.22 no.4
• /
• pp.421-428
• /
• 2012

The purpose of this study was to verify the effects of developed assisting wear which maximize trunk(back) muscle's stretch-shortening effect during backswing and downswing for increasing golf ball carrying distance. Design and fabrication of assistive wear were performed based on the results of analyzed data of trunk EMG activity from the golf drive swings of elite professional male golfers during back swing and downswing phases. After the prototype of wear was produced, surface EMG and Flight scope tests were conducted to verify the effectiveness of the wear for increasing distance to the professional golfers. Results indicated that wearing trial showed significant longer carry distance than the non-wearing trial(p<.001). The carry distance of wearing trial showed an average 229 m compared to the non-wearing trial, the average 225 m. The swing with wearing also produced significantly faster ball speed than the trial without wearing(p<.05). Average 245 Km/h and 244 Km/h were produced for the swing with and without wearing trails, respectively. EMG results also indicated that the muscle activity of left psoas was significantly increased for wearing trial during downswing and near the impact. Thus, this may affect positively to increase club head speed. The activity of the left latissimus dorsi was dramatically increased during the final stage of swing. This generates elongation effect for longer follow-through and increased impulse between club and ball so eventually valid assistance to increase carry distance. Therefore, the developed assisting wear was proved to be effective tool for increasing golf ball carry distance with maximizing trunk(back) muscle's stretch-shortening effect during backswing and downswing.

• The Journal of the Korea Contents Association
• /
• v.11 no.1
• /
• pp.350-356
• /
• 2011

The purpose of this study is to empirically examine how much the electronic clinical trial data management system actually enhances its efficiency. While the development of clinical trial markets highlights the significance of data management with increasing rate of adoption of electronic systems, its effects have not been fully supported with rigorous evidences. Particularly, the adoption rate of electronic clinical trial systems is low in domestic clinical trials markets. This study attempts to analyze the effect of the systems for reminding the importance of e-data management in clinical trials. The measurement indicator is experimented with the time related data collected from a multi-center clinical trial case. The result showed that the speed of the electronic clinical trial processes can be improved. The implication of this study lies in its first attempt to empirically analyze the effect of electronic clinical data management systems. Furthermore, application of the indicator in conjunction with electronic clinical trial processes is expected to facilitate strategic data management.

• The Journal of Internal Korean Medicine
• /
• v.10 no.1
• /
• pp.137-155
• /
• 1989

In order investigate the effect of Boyanghwanotang (BT) on thrombosis, Sprague-Dawley rats injected endotoxin into the caudal vein were oral administrated solid extract of BT-182. 4mg/200g (Sample A) and 364.8mg/200g (Sample B), and then observed Platelet, fibrinogen, prothrombin time and FDP. Another group injected hydrocortisone acetate into the muscular rump were adopted to observe the effect of BT on elevated blood Viscosity, administrated Sample A and Sample B, thereafter measured body weight, body temperature, whole blood viscosity, plasma viscosity, hematocrit, RBC, WBC, hemoglobin, glucose, albumin, total protein, triglyceride, cholesterol and prothrombin time. 1. Platelet was increased significantly in Sample B compared with the control group. 2. Fibrinogen of the trial groups compared with the control group was increased, and revealed a significance in Sample B. 3. Prothrombin time was decreased significantly in the trial groups compared with the control group. 4. FDP was decreased in the trial groups compared with the control group. 5. Body weight was increased significantly in Sample B after 7 days, body temperature revealed a significance in the trial groups after 5 days. 6. Whole blood viscosity and plasma viscosity of lower shear rates, both were highly decreased in the trial groupn than the control group. 7. The increase of WBC and decrease of hematocrit, RBC and hemoglobin was showed in the trial groups, and Sample B revealed a significance on the increase of WBC and decrease of RBC. 8. The increase of prothrombin time and decrease of glucose, albumin, total protein, triglyceride and cholesterol was showed in the trial group, and Sample B revealed a Significance on the increase of prothrombin time and decrease of albumin, total protein and triglyceride. 9. As compare with Sample A and Sample B, generally Sample B was highly Significant. According to the above results, it was considered that Boyanghwanotang may be the curative effects for thrombosis and elevated blood viscosity.

• Asian-Australasian Journal of Animal Sciences
• /
• v.18 no.2
• /
• pp.230-234
• /
• 2005

The purpose of this experiment was to study the effect of varying levels of tryptophan on the performance and carcass character of broiler. Trial 1: Ninety-six, five-week-old male Hubbard chickens, average weight 1.97 kg, were used in the trial. All birds were allocated into 3 treatments of 32 birds each. Each bird was kept in an individual cage. The trial period was 3 weeks. Treatment 1: Tryptophan content 0.198%. Treatment 2: Tryptophan content 0.228%. Treatment 3: Tryptophan content 0.258%. Trial 2: Ninety-six, three-week-old male Hubbard chickens, average weight 1.23 kg, were randomly distributed into the following two treatments. Each treatment had 48 birds. Treatment 1: Tryptophan content 0.167%. Treatment 2: Tryptophan content 0.198%. Trial 3: Ninety-six, twoweek-old Hubbard chickens, average body weight 0.72 kg, were used in this experiment. There were three treatments as follows. Treatment 1. Tryptophan content 0.136%. Treatment 2. Tryptophan content 0.167%. Treatment 3. Tryptophan content 0.198%. The result of Trial 1 showed that the feed intake, performance, and carcass characteristics were not influenced by tryptophan content in the diet which between 0.198% and 0.258% (p>0.05). There was no significant difference (p>0.05) in feed intake in either treatment in Trial 2. However, weight gain, feed conversion efficiency, and most carcass characteristics in the 0.198% treatment were significantly better (p<0.05) than in the 0.167% treatment. There was a trend that feed intake increased with increasing level of tryptophan, but there was no significant difference in Trial 3. The weight gain and feed conversion efficiency were significantly reduced for the broiler in the 0.136% treatment. This series of experiment showed that broilers need about 0.198% of tryptophan.

• Journal of Arbitration Studies
• /
• v.27 no.4
• /
• pp.3-33
• /
• 2017

This paper examines some questions and issues of the effect of an arbitral award, and discusses about the restriction of the trial level in other separate actions permitted under the existence of grounds of setting aside arbitral award after the amendment of the Arbitration Act in 2016. Because there are no interests of litigation in the action for setting aside arbitral award due to the exclusion of res judicata by provisory clause of Article 35, filing an action for setting aside is not allowed even when the grounds of setting aside exist. If we examine the precedent on possibility of retrial for excluding the outward form of invalid judgement, we can find that the court did not approve the retrial. Therefore, the action for setting aside that which is for excluding the outward form of an arbitral award will not be allowed for filing. On the issue of whether an arbitral award having a ground for setting aside can be an object of the action for setting aside for excluding its outward form or not, the views of scholars are divided. In the case of an arbitral award that has grounds for setting aside, it could be interpreted that the arbitral award would not have a formale Rechtskraft or effect of sentence (bindende Kraft). Even if there is formale Rechtskraft or effect of sentence (bindende Kraft), the significance of existence of action for setting aside arbitral award under paragraph 1 of Article 36 is reduced because other actions separate from arbitration is permitted under the 2016 Act. The amendment of the Arbitration Act in 2016 provides an opportunity to review the position and the role of action for setting aside the arbitral award. It also requires further studies on efficiently treating other actions separate from arbitration. Because the restriction of the trial level of other separate actions can make arbitration active by making arbitration procedures become 3 trial levels from 4 trial levels, it needs to be solved with legislative action. Specifically, if the trial starts at the stage of trial on appeal, it can utilize the strength of both the arbitration and the litigation, playing a chief role in boosting arbitration by removing the problems of action for setting aside and enabling arbitration institutes and the person interested to promote the activation of arbitration.

• Journal of Korean Society for Quality Management
• /
• v.39 no.2
• /
• pp.329-336
• /
• 2011

The purpose of Phase I clinical trial is to identify the maximum tolerated dose with specific toxicity rate. The standard TER design does not guarantee the pre-specified toxicity rate. It depends on the dose-toxicity curves. Therefore it is necessary to check the expected toxicity rate of various dose-toxicity curves before we conduct clinical trials. We developed TERAplusB library to help this situation, especially in cancer research. This package will help design the cancer clinical trial. We can compare the expected toxicity rates, the expected number of patients, and the expected times calculated with various dose-toxicity curves. This process will help find the best clinical trial design of the proposed drug.